Motilium (Domperidone)

Domperidone, the active ingredient in Motilium, is a dopamine D2 receptor antagonist presented as an oral tablet for systemic use. It is employed to relieve nausea and vomiting, improve gastric emptying in gastroparesis, and alleviate symptoms of functional dyspepsia in adult patients.

GNH USA supplies Motilium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Domperidone acts on peripheral dopamine pathways to manage several gastrointestinal and emetic conditions.

Nausea and vomiting: reduces episodes by blocking peripheral dopamine receptors in the chemoreceptor trigger zone. Gastroparesis: enhances gastric motility to improve stomach emptying. Functional dyspepsia: relieves upper abdominal discomfort by promoting gastrointestinal transit.

Domperidone is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Abdominal cramps: mild gastrointestinal discomfort. - Headache: transient cephalic pain. - Dizziness: sensation of light‑headedness. - Diarrhoea or constipation: altered bowel habits. - Fatigue: feeling of reduced energy.

Serious or Rare Side Effects: - Cardiac arrhythmia or QT prolongation: may lead to serious rhythm disturbances. - Extrapyramidal symptoms: rare movement disorders. - Hyperprolactinemia or galactorrhoea: hormonal effects causing breast discharge. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Hepatotoxicity: liver enzyme elevation. - Neuroleptic malignant‑like syndrome: extremely rare but life‑threatening condition.

Before prescribing domperidone, clinicians should consider several safety aspects.

Assess cardiac risk: evaluate QT interval in patients with known cardiac disease. Avoid in prolactin‑dependent tumors: contraindicated in patients with pituitary adenomas. Use caution in hepatic impairment: dose may need adjustment in liver dysfunction. Monitor electrolytes: especially potassium and magnesium levels to reduce arrhythmia risk. Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Domperidone may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase domperidone plasma levels. - QT‑prolonging drugs (e.g., quinidine, sotalol): additive risk of arrhythmia. - Antifungal agents (e.g., itraconazole): raise systemic exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Anticholinergic agents: may enhance anticholinergic side effects. - Macrolide antibiotics (e.g., clarithromycin): moderate increase in domperidone concentrations.